Seeking AlphaMon, 08 Jun 2026 17:08:31 GMTTravere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptTVTX+0.39%
Seeking AlphaTue, 02 Jun 2026 15:32:14 GMTTravere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines TranscriptTVTX+0.39%
Seeking AlphaWed, 13 May 2026 23:30:45 GMTTravere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptTVTX+0.39%
BenzingaTue, 05 May 2026 18:41:08 GMTTravere Therapeutics Analysts Increase Their Forecasts Following Q1 EarningsTVTX+0.39%
Seeking AlphaTue, 05 May 2026 11:21:15 GMTTravere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call TranscriptTVTX+0.39%
Zacks Investment ResearchMon, 04 May 2026 23:01:13 GMTCompared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key MetricsTVTX+0.39%
Zacks Investment ResearchMon, 04 May 2026 22:10:20 GMTTravere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue EstimatesTVTX+0.39%
Zacks Investment ResearchTue, 28 Apr 2026 10:56:10 GMTXOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?TVTX+0.39%
Seeking AlphaTue, 21 Apr 2026 19:40:43 GMTTravere Therapeutics: Still Undervalued Post FSGS ApprovalTVTX+0.39%
The Motley FoolMon, 20 Apr 2026 19:00:37 GMTTravere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started?TVTX+0.39%
Investors Business DailyFri, 17 Apr 2026 16:16:04 GMTFour Biotech Stocks Near Buy Points As Earnings Season Kicks InTVTX+0.39%
Seeking AlphaWed, 15 Apr 2026 19:21:56 GMTTravere Therapeutics: Re-Rating Potential As Filspari Wins Full ApprovalTVTX+0.39%
Zacks Investment ResearchWed, 15 Apr 2026 15:41:14 GMTTVTX Stock Soars on FDA Nod for Filspari in Second Kidney IndicationTVTX+0.39%
Zacks Investment ResearchWed, 15 Apr 2026 11:20:35 GMTTravere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?TVTX+0.39%
BenzingaTue, 14 Apr 2026 13:55:56 GMTFDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease PatientsTVTX+0.39%
Investors Business DailyTue, 14 Apr 2026 13:02:39 GMTTravere Therapeutics Stock Skyrockets On FDA ApprovalTVTX+0.39%
Seeking AlphaTue, 14 Apr 2026 02:41:44 GMTTravere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS TranscriptTVTX+0.39%
